Elite Pharmaceuticals Inc (ELTP) Financial Statements (2024 and earlier)

Company Profile

Business Address 165 LUDLOW AVENUE
NORTHVALE, NJ 07647
State of Incorp. NJ
Fiscal Year End March 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q2
6/30/2023
Q1
3/31/2023
Q4
12/31/2022
Q3
9/30/2022
Q2
6/30/2022
Q1
3/31/2022
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9,0777,83217,90918,55519,7808,535
Cash and cash equivalents9,0777,83217,90918,55519,7808,535
Receivables6,2013,0955,5464,2303,9653,058
Inventory, net of allowances, customer advances and progress billings11,1689,5518,6027,4687,6176,741
Inventory11,1689,5518,6027,4687,6176,741
Other undisclosed current assets9981,0331,108220508527
Total current assets:27,44521,51033,16530,47331,87018,861
Noncurrent Assets
Operating lease, right-of-use asset81319249811,032
Property, plant and equipment10,09810,42610,23010,5445,7555,953
Intangible assets, net (including goodwill)6,3416,3416,6346,6346,6346,634
Intangible assets, net (excluding goodwill)6,3416,3416,6346,6346,6346,634
Restricted cash and investments415412497497697497
Deferred income tax assets2,1722,1722,1722,1722,1722,172
Other undisclosed noncurrent assets2121    
Total noncurrent assets:19,05519,38619,55119,87116,23816,288
TOTAL ASSETS:46,49940,89652,71650,34348,10835,149
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,8047,4956,14810,44310,7076,131
Interest and dividends payable85617
Taxes payable3,9254,165
Employee-related liabilities13156
Accounts payable1,8752,4471,4721,7241,6141,431
Accrued liabilities5,9295,0484,6764,5784,8104,693
Deferred revenue131313  13
Debt251311471503435354
Other undisclosed current liabilities4,0091521(4,103)(4,062)196
Total current liabilities:12,0777,8346,6546,8437,0806,694
Noncurrent Liabilities
Long-term debt and lease obligation3,5783,56215,48915,53513,9892,225
Long-term debt, excluding current maturities3,5783,56215,48915,53213,2071,389
Liabilities, other than long-term debt7275413987741,5061,008
Deferred revenue161922262932
Other liabilities     4139
Operating lease, liability    2782836
Derivative instruments and hedges, liabilities7115223767491,437937
Total noncurrent liabilities:4,3054,10215,88716,30915,4953,233
Total liabilities:16,38211,93622,54223,15222,5759,927
Equity
Equity, attributable to parent30,11728,96030,17527,19125,53325,222
Common stock1,0141,0141,0141,0141,0111,011
Treasury stock, value(307)(307)(307)(307)(307)(307)
Additional paid in capital164,766164,751164,736164,723164,583164,577
Accumulated deficit(135,356)(136,498)(135,269)(138,239)(139,754)(140,060)
Total equity:30,11728,96030,17527,19125,53325,222
TOTAL LIABILITIES AND EQUITY:46,49940,89652,71650,34348,10835,149

Income Statement (P&L) ($ in thousands)

9/30/2023
Q2
6/30/2023
Q1
3/31/2023
Q4
12/31/2022
Q3
9/30/2022
Q2
6/30/2022
Q1
3/31/2022
Q4
Revenues8,9809,5659,2508,5867,67311,277
Cost of revenue(4,230)(4,352)(4,331)(4,761)(3,675)(6,483)
Gross profit:4,7515,2134,9193,8243,9984,794
Operating expenses(3,149)(5,756)(2,960)(2,743)(2,975)(2,895)
Operating income (loss):1,602(543)1,9591,0811,0231,899
Nonoperating income (expense)(305)(1,087)1,050446(717)(221)
Interest and debt expense(119)(986)(323)(243)(217)47
Income (loss) from continuing operations before equity method investments, income taxes:1,177(2,617)2,6871,284891,724
Other undisclosed income (loss) from continuing operations before income taxes119986323243217(47)
Income (loss) from continuing operations before income taxes:1,297(1,630)3,0091,5273061,677
Income tax expense (benefit)(155)(420)(39)(12)  
Other undisclosed income from continuing operations      1,736
Income (loss) from continuing operations:1,142(2,050)2,9701,5153063,414
Income before gain (loss) on sale of properties:1,5153063,414
Net income (loss):1,142(2,050)2,9701,5153063,414
Other undisclosed net loss attributable to parent  (857)   (87)
Net income (loss) available to common stockholders, basic:1,142(2,908)2,9701,5153063,327
Dilutive securities, effect on basic earnings per share6581,108373688  
Other undisclosed net loss available to common stockholders, diluted     (1,425)
Net income (loss) available to common stockholders, diluted:1,800(1,799)3,3432,2033061,902

Comprehensive Income ($ in thousands)

9/30/2023
Q2
6/30/2023
Q1
3/31/2023
Q4
12/31/2022
Q3
9/30/2022
Q2
6/30/2022
Q1
3/31/2022
Q4
Net income (loss):1,142(2,050)2,9701,5153063,414
Comprehensive income (loss), net of tax, attributable to parent:1,142(2,050)2,9701,5153063,414

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: